ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

Central Line Safety Intervention Lowers Patient Infection Rate

October 25, 2013

Advisers Discuss What To Do About Physician-Scientists

May 1, 1992

Margaret Edwards, 80, Cancer Education Pioneer, Dead

September 16, 1994

GSK’s Votrient Approved For Advanced Kidney Cancer

October 30, 2009

Dingell: “Unable To Vouch” For Staff Report On NCI’s Gallo

February 10, 1995

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013